FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Cirrhosis topics
Hypertension
Vascular Disease
Endothelial Dysfunction
Endothelial
Dysfunction
Cardiovascular Disease
Cardiovascular
Hepatocellular Carcinoma
Pharmaceutically Acceptable Salt
Pharmaceutically Acceptable Salts
Nephropathy
Nucleic Acid
Inflammation
Recombinant
Wound Healing

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cirrhosis patents



      
           
This page is updated frequently with new Cirrhosis-related patent applications. Subscribe to the Cirrhosis RSS feed to automatically get the update: related Cirrhosis RSS feeds. RSS updates for this page: Cirrhosis RSS RSS


Date/App# patent app List of recent Cirrhosis-related patents
07/02/15
20150182572
 Plant extract and the process for treating hepatic fibrosis and liver cancer patent thumbnailnew patent Plant extract and the process for treating hepatic fibrosis and liver cancer
An extract of graptopetalum paraguayense prepared by a method that includes: extracting a graptopetalum paraguayense (gp) starting material with an alcoholic solvent to produce an alcoholic extract and a residue; separating the residue from the alcoholic extract; extracting the residue with an aqueous dimethyl sulfoxide (dmso) solvent to produce a dmso extract; subjecting the dmso extract to ultrafiltration using a filter having a selected molecular weight cutoff; drying a fraction retained by the filter to obtain the extract of graptopetalum paraguayense. Uses of an extract of graptopetalum paraguayense for the treatment or prevention of liver fibrosis, hepatic cirrhosis, liver cancer, recurrence of liver fibrosis after surgery, or recurrence of liver cancer after surgery..
07/02/15
20150181844
 Fumarylacetoacetate hydrolase (fah)-deficient pigs and uses thereof patent thumbnailnew patent Fumarylacetoacetate hydrolase (fah)-deficient pigs and uses thereof
Described herein is the generation of fah+/− heterozygote pigs by homologous recombination and somatic cell nuclear transfer, and a method for producing fah−/− homozygote pigs. The fah-deficient pigs of the disclosure can be used for a variety of research and therapeutic purposes, such as for the expansion of human hepatocytes, and as large animal models of hereditary tyrosinemia type 1, cirrhosis and hepatocellular carcinoma..
06/25/15
20150174103
 Urea compounds and their use as enzyme inhibitors patent thumbnailUrea compounds and their use as enzyme inhibitors
Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis..
06/18/15
20150168426
 Methods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension patent thumbnailMethods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension
The present invention relates to a method for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension comprising the steps consisting of i) quantifying the levels of leuko-endothelial (cd31+/41−), pan-leukocyte (cd11a+), lymphocyte (cd4+), erythrocyte (cd235a+) and hepatocyte-derived (cytokeratin-18+) microparticles in a blood sample obtained from the patient and ii) comparing said levels with predetermined reference values wherein a difference between the levels quantified at step i) and the predetermined reference values is indicative whether the patient is at risk of having clinically significant portal hypertension.. .
Assistance Publique - Hopitaux De Paris
06/04/15
20150150897
 Methods of treating hepatitis c virus infection in subjects with cirrhosis patent thumbnailMethods of treating hepatitis c virus infection in subjects with cirrhosis
Methods of treating hepatitis c virus infection in a subject with cirrhosis comprising administering to the subject an effective amount of compound 1.. .
Gilead Pharmasset Llc
05/28/15
20150148658
 Method for the detection and staging of liver fibrosis from image acquired data patent thumbnailMethod for the detection and staging of liver fibrosis from image acquired data
This invention relates to methods for ascertaining at least one of liver fibrosis or cirrhosis in a subject, by processing of one or more medical images of the liver, using a computing machine, to quantify nodularity of the surface of the liver and calculate a liver surface nodularity score.. .
University Of Mississippi Medical Center
05/21/15
20150141501
 Ultrapure tetrahydrocannabinol-11-oic acids patent thumbnailUltrapure tetrahydrocannabinol-11-oic acids
This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.. .
Corbus Pharmaceutics Inc.
05/14/15
20150132370
 Composition and methods for reduced scarring and treatment of fibrosis patent thumbnailComposition and methods for reduced scarring and treatment of fibrosis
Embodiments of the present disclosure are directed to methods of treating, reducing or preventing fibrosis or scarring including administering a therapeutic molecular agent selected from the group consisting of an agent that inhibits chaperonin containing t-complex polypeptide subunit eta polypeptide (“cct-eta”), an agent that inhibits α-smooth muscle actin (“α-sma”), or a combination thereof. In embodiments, the fibrosis may include dupuytren's contracture, peyronie's disease, pulmonary fibrosis, cirrhosis, interstitial lung disease or scarring alopecia..
05/14/15
20150132289
 Methods and compositions for treating psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) with anti-cd3 immune molecule therapy patent thumbnailMethods and compositions for treating psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) with anti-cd3 immune molecule therapy
A method or composition comprising an anti-cd3 immune molecule for treatment of psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) in a subject.. .
05/07/15
20150126432
 V1a receptor agonists patent thumbnailV1a receptor agonists
Compounds of formula (i), salts thereof, and compositions and uses thereof are described. The compounds are useful as v1a vasopressin agonists, for the treatment of e.g., complications of cirrhosis, including bacterial peritonitis, hrs2 and refractory ascites..
Ferring B.v.
04/23/15
20150111937

Compositions and methods for treating intestinal hyperpermeability


The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .
04/23/15
20150111878

Compositions and methods for treating intestinal hyperpermeability


The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .
04/16/15
20150105293

Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers


The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis.
The Chancellor, Masters And Scholars Of The University Of Oxford
04/09/15
20150098926

Methods of treating hepatitis c virus infection


The present invention provides methods of treating hepatitis c virus (hcv) infection; methods of reducing the incidence of complications associated with hcv and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from hcv infection. Also provided are methods of treating liver steatosis and liver fibrosis..
The J. David Gladstone Institutes
04/02/15
20150094277

Combination therapy and methods for treatment and prevention of hyperproliferative diseases


The present invention provides therapy and methods for the treatment and prevention of diseases of cell proliferation such as cancer, benign tumors, and viral diseases such as hiv-aids, hepatitis b, hepatitis c and cirrhosis. The methods of this invention consist of the administration to a patient of a combination of effective amounts of agents capable of eradicating the neoplastic cells, while sparing the non-neoplastic cells from cytotoxic side-effects.
03/26/15
20150087639

Nitrogenous heterocyclic derivatives and their application in drugs


The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis..
Sunshine Lake Pharma Co., Ltd.
02/26/15
20150057170

Method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens


Methods and compositions are described for the diagnosis of primary biliary cirrhosis. Novel autoantigens are described for use in assays which employ test samples from individuals..
Massachusetts General Hospital
01/29/15
20150031771

Pharmaceutical composition for preventing or treating hepatic fibrosis and cirrhosis containing ramalin


There is provided a novel use of ramalin for preventing or treating liver diseases, and more specifically, a pharmaceutical composition for preventing or treating hepatic fibrosis or cirrhosis containing ramalin or a pharmaceutically acceptable salt thereof, and a functional food containing the same. It was confirmed that at the time of applying ramalin, which is a compound derived from ramalina terebrata according to the present invention, to animal models, ramalin may remarkably suppress hepatic fibrosis and lower liver cirrhosis levels as compared to silymarin known as a liver cell protecting ingredient without cytotoxicity to normal liver cells, such that ramalin may be effectively used for preventing or treating hepatic fibrosis and liver cirrhosis..
Korea Institute Of Ocean Science And Technology
01/29/15
20150031027

Use of saa1 beta/beta homozygote in the prognosis diagnosis and diagnosis of liver cirrhosis


Provided is uses of saa1β/β(1.5/1.5) homozygote in prognosis and/diagnosis of liver cirrhosis, and in preparation of a reagent for liver cirrhosis prognosis and/or liver cirrhosis diagnosis. Recognition of liver cirrhosis susceptible populations can be achieved by detection of human saa1β/β homozygote and non-saa1β/β homozygote through real-time fluorescence quantitative allele specific pcr..
01/15/15
20150018299

Treatment of liver conditions


The present disclosure concerns the a3 adenosine receptor agonist, 2-chloro-n6-(3-iodobenzyl)-adenosine-5′-n-methyluronamide (cl-ib-meca) in an amount of at least about 10 mg/day, for use in treatment of hepatocellular carcinoma (hcc). The present invention also provides cl-ib-meca for use in maintenance of liver function in a subject having a chronic liver disease, such as cirrhosis.
Can-fite Biopharma Ltd.
12/04/14
20140357733

Methods relating to identification of susceptibility to liver injury


The present invention relates to methods for identifying susceptibility of impaired hepatic wound healing in a patient, most particularly by identifying modifications of the of ppar-γ and tgfβ1 genes. It further relates to stratifying populations of patients to determine susceptibility to impaired hepatic wound healing and direct appropriate healthcare resources.
11/06/14
20140329900

Small molecule inhibitors of stat3 with anti-tumor activity


The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, nsc 74859 (s31-201), nsc 42067, nsc 59263, nsc 75912, nsc 11421, nsc 91529, nsc 263435, and pharmaceutically acceptable salts and analogs of the foregoing.
11/06/14
20140329747

Compositions and methods for treating renal failure


The present disclosure relates to the use of angiotensin ii in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis.. .
09/18/14
20140271954

Toxin expelling powder comprising root of buckwheat and preparation process thereof


The present invention provides tartary buckwheat detox powder and a method for preparing the same. Raw materials are loveyly hemsleya root, sophora flavescens root, tartary buckwheat and dried ginger.
09/04/14
20140249209

Methods for the treatment and prevention of liver disease


The presently disclosed invention is directed to the discovery that hepatocyte nuclear factor 4 alpha (hnf4α; also known as nr2a1), a transcription factor, reverses hepatocyte dysfunction in an animal model of cirrhosis, resulting in improvement in hepatic function, treatment of cirrhosis, and prolonged survival.. .
08/21/14
20140234288

Lysosomal acid lipase therapy for nafld and related diseases


The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating the metabolic syndrome.
08/07/14
20140221350

Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists


The present invention provides 4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as v1a receptor modulators, and in particular as v1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior..
07/10/14
20140193431

Anti-c-met antibody having hgf activity and use thereof


Disclosed are a human antibody comprising a human complementarity-determining region (cdr), which binds specifically to c-met, and a framework region (fr), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody b7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-met-specific human antibody can function as an hgf mimic that can be used as a wound healing composition.
07/03/14
20140187633

Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis


In various embodiments, the present invention provides methods of treating and/or preventing nash and/or pbc comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.. .
07/03/14
20140187504

Prevention and treatment of inflammatory conditions


The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ald). More specifically the present embodiments relate to the prevention and treatment of ald through the administration of an retinoic acid receptor (rar) agonist.
06/26/14
20140179726

Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction


A systems biology approach is used to characterize and relate the intestinal (gut) microbiome of a host organism (e.g. A human) to physiological processes within the host.
06/12/14
20140162286

Method for the detection of enzymatic activity with magnetically functionalized substrates


The present invention provides methods for detecting an enzymatic activity, the method including combining at least one magnetic particle to an enzyme substrate to form a magnetically modified substrate, reacting the magnetically modified substrate with at least one enzyme; and detecting a change in a magnetic property of the magnetically modified substrate or its cleavage products, thereby detecting an activity of said at least one enzyme, wherein the method may be applied to a human subject to detect a disease selected from the group consisting of rheumatitis, arthritis, an injury, dupuytren's disease, peyronie's disease, a collagen related disease, steatosis, fibrosis, cirrhosis, metastasis, tissue regeneration, cancer, coronary disease, a liver disease, a metabolic condition, an infection and an inflammatory disease.. .
05/15/14
20140134751

Diagnostic method


Disclosed herein is a method for diagnosing hepatic cancer by analysing a sample and determining the level of at least one compound selected from the group consisting of glycine, trimethylamine-n-oxide, hippurate and citrate and comparing the levels in the sample with control levels. The analysis of the sample can involve the determination of a profile for the sample.
03/27/14
20140086984

Pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and pharmaceutically acceptable salt or derivative thereof


The present invention provides a new use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and pharmaceutically acceptable salt or derivative thereof. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including mmps and timps, and so it can inhibit liver fibrosis.
03/13/14
20140073606

2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections


The present invention relates to 2′-fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including hepatitis b virus (hbv) and secondary disease states and conditions thereof (cirrhosis and liver cancer), heptatitis c virus (hcv), herpes simplex virus i and ii (hsv-1 and hsv-2), cytomegalovirus (cmv), varicella-zoster virus (vzv) and epstein barr virus (ebv) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses, especially hbv.. .
02/13/14
20140045718

Biomarkers for inflammation of the liver


The invention relates to a method for the diagnostic investigation of biological samples from a person for inflammation of the liver, in particular hepatic fibrosis and/or cirrhosis of the liver, where the sample is investigated for one or more proteins as markers of inflammation of the liver, in particular hepatic fibrosis and/or cirrhosis of the liver, where a concentration of the proteins which is elevated or decreased by comparison with the healthy state indicates the presence of an inflammation of the liver, in particular a hepatic fibrosis and/or cirrhosis of the liver.; the proteins are selected from the group of er6q, vimentin, actin alpha 1 skeletal muscle protein, hmfap 4, tropomyosin, ptges 2, amyloid p component, transgelin, calponin 1, homo sapiens p20 protein, 17 kda myosin light chain, h chain h igg b12, prolyl 4-hydroxylase, beta subunit methylenetetrahydrofolate dehydrogenase 1, pro2619, aldehyde dehydrogenase 1, fibrinogen alpha chain preproprotein, fructose-bisphosphate aldolase b, argininosuccinate synthetase, eefla2, at p 5 al, alpha-2 actin, regucalcin, serum albumin, mitochondrial malate dehydrogenase, mitochondrial acetoacetyl-coa thiolase or in each case a partial sequence thereof.. .
12/19/13
20130337055

Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection


The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including hepatitis b and hepatitis c viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions..
11/21/13
20130309202

Methods for improving liver function


The present invention provides methods to improve liver function utilizing tocotrienols. In particular, various liver pathologies may be treated using the present methods, including cirrhosis, hepatitis, and sclerosing cholangtitis.
11/14/13
20130302335

Ligands that bind tgf-beta receptor ii


The disclosure provides an anti-tgfbetarii immunoglobulin single variable domain. Suitably, an anti-tgfbetarii immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of seq id no:1-28 having up to 5 amino acid substitutions, deletions or additions.
11/07/13
20130296278

Diazeniumdiolate derivatives


A compound having the structure (i) useful for treating hypertension, pulmonary arterial hypertension, congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.. .
10/31/13
20130289003

Diazeniumdiolate heterocyclic derivatives


A compound having the structure: useful for treating hypertension, pulmonary arterial hypertension (pah), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.. .
10/17/13
20130273006

Methods and compositions for the treatment of cirrhosis and liver fibrosis


The invention provides a method for the treatment of cirrhosis and liver fibrosis by the use or viral vectors containing the gene encoding igf-i. The invention discloses both parvoviral vectors and sv40-based vectors as well uses thereof for the treatment of cirrhosis and gene therapy and methods for the preparation of said viral vectors..
10/10/13
20130267797

Method for enhancing the performance and general condition of a subject


The invention concerns the therapy with a cardiac resynchronization device (crt) and/or therapy with an automated internal cardiac defibrillator (icd) for treating patients with any cancer or patients with cachexia due to acute or chronic illness other than cardiac illness, including malignant tumor disease, copd, chronic renal failure, liver cirrhosis, chronic infections, and/or aids. Areas of application are the life sciences, in particular medicine and medical technology..
09/26/13
20130252885

Fused tricyclic compounds as adenosine receptor antagonist


The present disclosure relates to fused tricyclic compounds of formula (i) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as a2a adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine a2a receptor.
09/12/13
20130237456

Marker consisting of plasma microrna and a new diagnosis of hepatocellular carcinoma


The present invention relates to a kit for diagnosing hepatocellular carcinoma consisting of plasma microrna, a kit containing the same, and a new method therefor. The marker for diagnosing hepatocellular carcinoma consists of a plurality of nucleic acid molecules, each nucleic acid molecule encoding at least one microrna sequence, preferably consists of nucleic acid molecules encoding hsa-mir-122, hsa-mir-192, hsa-mir-21, hsa-mir-223, hsa-mir-26a, hsa-mir-27a, hsa-mir-801 and hsa-mir-1228.
08/15/13
20130210798

Soluble guanylate cyclase activators


This inventions relates to compounds having the structure formula i and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver..
08/08/13
20130202646

Compositions and methods for modulating autophagy


In alternative embodiments, the invention provides cell-permeable recombinant or synthetic proteins to modulate autophagy, including a tat-atg5k130r (inhibitor of autophagy) and a tat-beclin 1 (stimulant or activator of autophagy), and nucleic acids expressing them and methods for making and using them, e.g., to treat conditions and disorders responsive to autophagy modulation (e.g., where autophagy is dysregulated), including neurodegeneration, cystic fibrosis, cancer, heart failure, diabetes, obesity, sarcopenia, aging, ischemia/reperfusion, inflammatory disorders including crohns, ulcerative colitis, biliary cirrhosis, lysosomal storage diseases, infectious diseases associated with intracellular pathogens including viruses, bacteria, and parasites such as trypanosomes and malaria.. .
08/01/13
20130197893

Methods for modeling hepatic inflammation


Provided herein are in silico methods of modeling hepatic inflammation, fibrosis/cirrhosis, and cancer. The models are computer-implemented agent-based models and are useful in determining patient prognoses in hepatic conditions, including viral infections, damage, inflammation, and cancer.
07/25/13
20130191931

Fumarylacetoacetate hydrolase (fah)-deficient pigs and uses thereof


Described herein is the generation of fah+/− heterozygote pigs by homologous recombination and somatic cell nuclear transfer, and a method for producing fah−/− homozygote pigs. The fah-deficient pigs of the disclosure can be used for a variety of research and therapeutic purposes, such as for the expansion of human hepatocytes, and as large animal models of hereditary tyrosinemia type 1, cirrhosis and hepatocellular carcinoma..
07/18/13
20130184307

Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders


Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of s1p1-associated disorders, for example, psoriasis, rheumatoid arthritis, crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type i diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer.. .


Popular terms: [SEARCH]

Cirrhosis topics: Hypertension, Vascular Disease, Endothelial Dysfunction, Endothelial, Dysfunction, Cardiovascular Disease, Cardiovascular, Hepatocellular Carcinoma, Pharmaceutically Acceptable Salt, Pharmaceutically Acceptable Salts, Nephropathy, Nucleic Acid, Inflammation, Recombinant, Wound Healing

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cirrhosis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cirrhosis with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





3.1515

3364

459475 - 0 - 71